Sunday, February 5, 2012
"The source for European pharmaceutical biotechnology news..."
Sponsors
Platinum Sponsors
Blog
Spencer Green
Chairman, GDS International
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?25 May 2011
White Papers
Focus Areas
Cover Stories
The Small Company That Grew
Once a minor force in the world pharmaceutical market, Nycomed became a major player following its acquisition of Altana Pharma in 2006. CEO...
Winner takes all
The competition between branded drugs and generic copies has been going on for years, but as generics threaten to take the lead, how will...
In with the new
When Chris Viehbacher arrived to take up the reins as CEO of sanofi-aventis at the end of last year, he found a company with an image problem...
Roundtables
-
Challenges in drug development and delivery
John Fraher of Eurand and Gerd Paulus of Swiss BioAnalytics talk to NGP about common problems in developing successful pharmaceutical products.Read more -
Keeping it Lean
NGP talks to four industry experts about the applications of Lean and Six Sigma in pharmaceutical manufacturing. With JMP, R&G Global Consultants, SI Associates, and...Read more -
The importance of CRM
CRM Roundtable with Rob Halkes of Van Spaendonck, Vivian Hunt of McKinsey & Company and CDM’s Torben Vogt.Read more -
Strategies for successful marketing
Four experts give NGP the inside scoop on the latest techniques for establishing and promoting brand awareness. With Corbett Accel Healthcare Group’s Scott Cotherman, Grey...Read more
Vendor Perspectives
-
Cyclobenzaprine ER: partnering for succe...
By Eurand. Patients’ unmet needs due to inconvenient dosing and significant side effects with existing therapies led to the collaboration to develop Amrix®, the first and...Read more -
Like a bridge over troubled waters: Neow...
Bringing a new drug to market is one of the riskiest ventures in the business world. Ms. Ayelet Dilion-Mashiah, VP Business Development at Do-Coop Technologies, explains...Read more -
High functionality in a very compact space
Compact process layouts with Robolux valves from Bürkert.Read more -
One-click global regulatory overview in ...
Actavis, one of the world’s leading generic pharmaceutical firms, launched CDM Regulatory Manager in 2005. The solution is implemented in 65 countries, enabling a...Read more -
The see vs. solve challenge
By Aegis Analytical. Manufacturers are continuously working to improve processes for better yields, faster time to market and fewer regulatory investigations. Aegis...Read more -
Nature Publishing Group and Biocentury l...
The publisher of Nature, the world’s most prestigious science journal, and Biocentury, a leading provider of intelligence on the pharmaceutical and biotech industry, have...Read more
Industry Analysts
-
Utilising cutting-edge water-based nanotec...
By Ayelet Dilion-Mashiah, Do-Coop Technologies Ltd. Bringing a new drug to market is one of the most expensive procedures in the business world. As the costs of new drug...Read more -
Sound responses to the changing late-phase...
Safety concerns in drug development, both from the public and regulators, have clearly intensified – and there will be no let up. By Dipti Amin, QuintilesRead more -
Strategic choices to reduce acetonitrile d...
By Richard Lake, Restek Corporation. In today’s economic climate, laboratory productivity is an increasingly important key to bringing new drugs to market efficiently, and...Read more -
Towards more affordable and innovative pha...
Abhijit Mukherjee of Dr. Reddy’s explains the current woes currently facing the pharmaceutical industry.Read more -
An airfreight-focused logistics solution
By Martin Svantesson, Geodis WilsonRead more -
Laboratory asset management strategies
Masao Moriyama explains how using a single provider for the management of laboratory equipment throughout its entire lifecycle reduces administration, improves efficiency...Read more
Executive Interviews
Starting at phase zero
Michael Butler of Xceleron looks at the value a microdose study adds to a drug development programme.
Read more
The future of biomarker assays
Ralph McDade of Rules Based Medicine explains why more is better when it comes to data used to identify meaningful biomaker patterns.
Read more
Medical communications in a changing world
Amanda Smith of Caudex Medical explains the effects of the movement towards evidence-based medicine.
Read more
NGP Europe Summit: Drug Discovery
5th - 7th April 2011
The Next Generation Drug Discovery Summit Europe is designed to bridge the growing technological gap between drug discovery and drug development.
Source: www.ngpharma.eu.com© 2012 GDS Publishing Ltd. All rights reserved.